Newly designed investigational Cancer Stem Cell pathway Inhibitors

Boston Biomedical, an industry leader in the development of novel compounds designed to target cancer stem cell (CSC) pathways, will present clinical data on the investigational compounds BBI608 and BBI503 in multiple tumor types at the 2015 American Society of Clinical Oncology annual meeting, held from May 29 to June 2, 2015, in Chicago, IL.

Data to be highlighted at the meeting show the potential of BBI608, an orally-administered investigational agent that targets STAT3, leading to inhibition of the critical genes for maintaining cancer stemness for anti-cancer activity when used in combination with other chemotherapeutics across varying advanced cancers, including Gastric and Colorectal. The study protocol from the BRIGHTER study, the phase 3 clinical trial currently underway to investigate cancer stem cell pathway inhibitors, will also be showcased.

Additional data featuring BBI503,an orally-administered investigational agent designed to inhibit Nanog and other cancer stem cell pathways by targeting kinases showed encouraging early signs of anti-cancer activity for patients with advanced Colorectal Cancer.